This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Twenty Four Month Extension Study of BA058-05-003 (ACTIVExtend)

This study has been completed.
Information provided by (Responsible Party):
Radius Health, Inc. Identifier:
First received: July 31, 2012
Last updated: April 12, 2017
Last verified: April 2017
The purpose of this study is to provide 24 months of standard of care data on subjects previously enrolled in study BA058-05-003.

Condition Intervention Phase
Postmenopausal Osteoporosis Drug: Alendronate Phase 3

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Extension Study to Evaluate 24 Months of Standard-of-Care Osteoporosis Management Following Completion of 18 Months of BA058 (Abaloparatide) or Placebo Treatment in Protocol BA058-05-003

Resource links provided by NLM:

Further study details as provided by Radius Health, Inc.:

Primary Outcome Measures:
  • Safety [ Time Frame: 6 months ]
    Incidence and severity of Adverse Events, Fractures, and Changes in Clinical Laboratory Values

Secondary Outcome Measures:
  • Vertebral Fracture Incidence [ Time Frame: 6 months ]
  • Non-vertebral Fracture Incidence [ Time Frame: 6 months ]

Estimated Enrollment: 1200
Study Start Date: October 2012
Study Completion Date: October 2016
Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Alendronate
Drug: Alendronate


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

1. The subject was enrolled, randomized to either the BA058 (abaloparatide) or placebo arm, and successfully completed Study BA058-05-003.

Exclusion Criteria:

  1. Were withdrawn from Study BA058-05-003 for any reason.
  2. Experienced a treatment-related SAE during Study BA058-05-003.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01657162

  Show 27 Study Locations
Sponsors and Collaborators
Radius Health, Inc.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Radius Health, Inc. Identifier: NCT01657162     History of Changes
Other Study ID Numbers: BA058-05-005
ACTIVExtend Trial ( Other Identifier: Radius Health, Inc. )
Study First Received: July 31, 2012
Last Updated: April 12, 2017

Keywords provided by Radius Health, Inc.:
bone loss

Additional relevant MeSH terms:
Osteoporosis, Postmenopausal
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Bone Density Conservation Agents
Physiological Effects of Drugs processed this record on September 21, 2017